Expertise in
1
conditions

Guosheng H. Ren

Chongqing Key Laboratory Of Molecular Oncology And Epigenetics, 
Chongqing, CN 
Expertise in
1
conditions
Chongqing Key Laboratory Of Molecular Oncology And Epigenetics, 
Chongqing, CN 
OverviewLocationsClinical Research

Overview

Guosheng Ren practices in Chongqing, China. Ren is highly rated in 1 condition, according to our data. Their top areas of expertise are Breast Cancer, Breast Cancer in Men, Triple-Negative Breast Cancer, BRCA Positive Breast Cancer, and Mastectomy.

Their clinical research consists of co-authoring 153 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Locations

Chongqing Key Laboratory Of Molecular Oncology And Epigenetics, Chongqing, China
Other Locations
Yantai, 264001, China
No.1 Yixue Road, Yuzhong District, Yixue, 400016, China
Chongqing Key Laboratory Of Molecular Oncology And Epigenetics, No. 1 You Yi Road, Youyi, 400016, China
Minhang, 201199, China
No.1 Youyi Road, Yuzhong District, Yuanjiagang, 400016, China
Shanghai, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Enrollment Status: Unknown
Publish Date: April 19, 2017
Intervention Type: Drug
Study Drugs: 5-Fu/Epirubicin/CTX Following Docetaxel, Docetaxel/Capecitabine Followed by Capecitabine/Epirubicin/Cyclophosphamide
Study Phase: Phase 3

153 Total Publications

Integrating multi-omics and machine learning methods reveals the metabolism of amino acids and derivatives-related signature in colorectal cancer.
Integrating multi-omics and machine learning methods reveals the metabolism of amino acids and derivatives-related signature in colorectal cancer.
Journal: Frontiers in oncology
Published: January 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ren's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile